CD274 and neoplasm: However, these comparisons are questionable since the methods used to assess PD-L1 status differed according to the CheckMate-214/CheckMate-9ER, JAVELIN Renal 101 and KEYNOTE-426 studies: 28-8 clone (Dako), PD-L1 ≥ 1% in tumor cells, SP263 clone (Ventana), PD-L1 ≥ 1% in immune cells and 22C3 clone (Dako), Combined Positive Score (CPS) > 1% tumor cells plus immune cells, respectively [5,6,7,8,9,10,11].